Samsara BioCapital’s Founder and Managing General Partner is Dr. Srinivas Akkaraju. For the previous four years, he was the Managing Director of New Leaf Venture Partners. Enara Bio, IONpath, Levo Therapeutics, Nkarta Therapeutics, and Sutro are among the firms Michael Dybbs serves on the board of directors. Samsara BioCapital owns major holdings in many firms, including BioNTech SE, Novavax, and Allakos Inc., as of the second quarter of 2021.
Insider Monkey highlights the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. The latest addition to Srini Akkaraju and Michael Dybbs’ hedge fund portfolio is Elevation Oncology, Inc. Samsara BioCapital paid $12.65 million for 932,239 shares of the company. Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in developing and marketing medicines to treat non-viral liver diseases that advance. In the second quarter of 2021, hedge fund positions fell to 13, down from 15 the previous quarter. IVERIC bio, Inc. was created in 2007 and is now ranked 13th among the top 15 biotech stocks to purchase right now. It earned -$0.32 per share, missing projections by $0.06 per share. The stock of Aclaris Therapeutics, Inc. has increased by 587.40 percent in the previous year. In the second quarter of 2021, 37 hedge funds disclosed owning stakes in Aclaris, indicating that the firm is gaining traction. SpringWorks Therapeutics, Inc. was founded in 2017 and is now placed 11th on our list of the best biotech companies to buy right now. The number of hedge fund positions fell to 18 in the second quarter, down from 22 in the first quarter. For more details, click 15 Biotech Stocks To Buy Now According To Srini Akkaraju And Michael Dybbs’ Samsara BioCapital.
